Allogeneic UCB-derived CAR-T therapy for B-cell acute lymphoblastic leukemia

· The General Hospital of Western Theater Command

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Allogeneic UCB-derived CAR-T therapy for B-cell acute lymphoblastic leukemia, covering 2025-12-01 to 2025-12-01. Get the full timeline:

Most recent: Clinical Trial Update: Allogeneic UCB-derived CAR-T for B-ALL [EARLY_Phase 1]

See pricing